Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Hubro Therapeutics AS
AS
Bankrupt
Org 921833016
Ullernchausséen 64, 0379
Oslo
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2018 · 7 years old
9 employees
Monitor
Share
Norway
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Hubro Therapeutics AS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
NOK millions
1M
1M
1M
0M
0M
2019: 1M
1M
2019
2020: 0M (-100% vs 2019)
0M
-100%
2020
2021: 0M
0M
2021
2022: 0M
0M
2022
EBITDA
NOK millions
0M
-10M
-20M
-30M
-40M
2019: -2M
-2M
2019
2020: -8M (-300% vs 2019)
-8M
-300%
2020
2021: -8M (0% vs 2020)
-8M
0%
2021
2022: -32M (-300% vs 2021)
-32M
-300%
2022
Income statement
NOK thousands
Item
2022
2021
2020
2019
Revenue
0
54
0
750
Staff expenses
−7 016
−1 649
−2 904
−1 364
EBITDA
−31 701
−7 651
−7 554
−2 143
Depreciation & amort.
−11
−0
−0
−0
EBIT
−31 713
−7 651
−7 554
−2 143
Net financials
161
115
66
13
Profit before tax
−31 552
−7 537
−7 488
−2 130
Tax
−0
−0
578
−578
Net profit
−31 552
−7 537
−8 066
−1 552
Balance sheet
NOK thousands
Item
2022
2021
2020
2019
Total assets
83 592
71 600
15 023
5 991
Equity
36 468
68 020
14 056
5 622
Long-term debt
35 425
0
0
0
Short-term debt
11 699
3 580
967
369
Total debt
47 124
3 580
967
369
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2019
2022
Equity ratio
43,6 %
This company
38,2 %
Market median
This company
Market median
14% above market
2019
2022
Return on equity
−86,5 %
This company
18,4 %
Market median
This company
Market median
570% below market
2019
2022
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2019
2022
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2019
2022
Debt / equity
1,29×
This company
0,62×
Market median
This company
Market median
108% above market
2019
2022
Annual reports & filings
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via Brønnøysundsregistrene · Period 2018-11-20 – 2019-12-31
View
PDF
More on Hubro Therapeutics AS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
